New Techniques in Nutritional Research: 009 (Bristol-Myers Squibb Nutrition Symposia, Vol 9)
Star Tribune (Free subscription) | yesterday
Asterand, with offices in Detroit and the United Kingdom, will continue to provide drug discovery services and human tissue and clinical samples to Bristol-Myers Squibb. The tissue and samples will be used in research on potential drugs. The companies entered a three-year partnership in May 2007.
Business Wire (Free subscription) | yesterday
DETROIT--(BUSINESS WIRE)--Asterand plc (LSE: ATD), a leading provider of human tissue and human tissue-based services to pharmaceutical and biotechnology companies engaged in drug discovery research, today announced that it has extended its collaboration with Bristol-Myers Squibb Company (NYSE: BMY) for access to Asterand's products and services for up to three years. The agreement will focus on access...
The Street (Free subscription) | 11 hours ago
Origin Agritech, Rockwell Collins, Xcel Energy, Accenture and Bristol-Myers Squibb hit 52-week highs.
ABC News (Free subscription) | yesterday
Asterand says Bristol-Myers Squibb extends research partnership for 3 more years Bristol - Bristol-Myers Squibb - England - Society and Culture - Business
Seattle Post-Intelligencer (Free subscription) | yesterday
NEW YORK -- Drugmaker Bristol-Myers Squibb Co. and Asterand PLC are extending a research collaboration for up to three years, Asterand said Monday.
SeekingAlpha.com (Free subscription) | yesterday
Zacks.com submits: Recently, Bristol-Myers Squibb Co. ( BMY ) received approval from the U.S. Food and Drug Administration (FDA) to market Abilify (aripiprazole) for the treatment of irritability in pediatric patients having autistic disorder. Abilify can be used to treat children aged 6 to 17 years for symptoms of aggression toward others, deliberate self injury, temper tantrums and quick mood swings....
Seattle Times (Free subscription) | yesterday
Drugmaker Bristol-Myers Squibb Co. and Asterand PLC are extending a research collaboration for up to three years, Asterand said Monday.
BloggingStocks (Free subscription) | yesterday
Filed under: Analyst reports , Pfizer (PFE) , Market matters , Bristol-Myers Squibb (BMY) , Merck and Co (MRK) , Lilly (Eli) (LLY) , Deere and Co (DE) , Stocks to Buy , Potash Corp. of Saskatchewan (POT) From TheStreet.com Network Dollar Store: Early Volume Plays Dollar Could Steer Stocks in Coming Week TheStreet.com's Jim Cramer says it looks like the patent worries aren't so dire after all. Now...
Contract Pharma Breaking News (Free subscription) | yesterday
Asterand has extended its collaboration with Bristol-Myers Squibb for as many as three years, for access to Asterand's PhaseZERO drug discovery services and XpressBANK of human tissue and clinical samples for validation of early drug targets and support for compound optimization. Asterand chief executive officer, Martyn Coombs, commented: “This decision by BMS is an important validation of Asterand's...
Kapp Notes (Free subscription) | 21/11/2009
It's been a good 3 days of Bloomsburg University's Corporate Advisory Council meeting. We had great Corporate Presentations on Wednesday , the students did a Fantastic Job on Thursday and on Friday, Dr. Doll gave a great presentation highlighting Google Wave. Dr. Doll makes a point about Google Wave. Meanwhile, students interviewed with many companies including Kodak , RWD Technologies , Geisinger...
Business Wire (Free subscription) | 21/11/2009
PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for ABILIFY® (aripiprazole) for the treatment of irritability associated with autistic disorder in pediatric patients ages 6 to 17 years, including symptoms...
The IN VIVO Blog (Free subscription) | 20/11/2009
People, we seriously need to talk about Eggo Waffles. But first, a dearth of meaty deals this week has us thinking more about Bristol-Myers Squibb's share-swap/buyback/spin-off of its nutritionals unit Mead Johnson. We tried to make the point earlier this week that Bristol's move was too focused on short-term gain. Others have pointed out to us that without some sort of short-term gain to appease...
PR News Wire (Free subscription) | 20/11/2009
CHICAGO, Nov. 20 /PRNewswire/ -- Seven Summits Research issues PriceWatch Alerts for CVX, BMY, GFI, NVLS, and HST.
The IN VIVO Blog (Free subscription) | 19/11/2009
The Food & Drug Administration's public health alert on Plavix is, as we point out in "The Pink Sheet" DAILY , a nice boost for Eli Lilly and Daiichi Sankyo, who market the competing platelet agent Effient . But the back story to this regulatory action merits closer attention by all pharmaceutical sponsors. This is no ordinary labeling change, and the implications of how the regulatory...
Online Canada Pharmacy Blog (Free subscription) | 18/11/2009
Yesterday a report was released that found combining the heartburn medication Prilosec with the blood thinner Plavix can decrease the effectiveness of the blood thinner by 50 percent, putting the user at greater risk for strokes and heart attacks. “These recommendations are based upon recently submitted studies by the manufacturer of clopidogrel [Sanofi-Aventis and Bristol-Myers Squibb],”...
Videos